Xencor reported $-36110000 in EBITDA for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Alnylam Pharmaceuticals ALNY:US USD -247440000 65.85M
Amgen AMGN:US USD 3.5B 62M
Arrowhead Research ARWR:US USD -81170000 10.86M
AstraZeneca AZN:LN USD 3.6B 404M
Biogen BIIB:US USD 992.8M 82.9M
Bristol Myers Squibb BMY:US USD 5.32B 456M
Cytokinetics CYTK:US USD -107033000 97.57M
GlaxoSmithKline GSK:LN GBP 3.36B 916M
Johnson & Johnson JNJ:US USD 7.34B 1.2B
Karyopharm Therapeutics KPTI:US USD -30657000 12.1M
Macrogenics MGNX:US USD -22111000 16.82M
Novartis NOVN:VX USD 4.69B 34M
Pfizer PFE:US USD 10.52B 2.78B
Regeneron Pharmaceuticals REGN:US USD 1.33B 49.4M
Roche Holding ROG:VX 13.44B 2.56B
Seattle Genetics SGEN:US USD -175213000 59.32M
Xencor XNCR:US USD -36110000 10.33M